Clinical Trials Logo

Disease or R Group Histiocytoses clinical trials

View clinical trials related to Disease or R Group Histiocytoses.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04007848 Completed - Clinical trials for Disease or R Group Histiocytoses

Cobimetinib for BRAF-wild-type or Mutated Histiocytoses

COBRAH
Start date: July 25, 2019
Phase: Phase 3
Study type: Interventional

COBRAH is a randomized double-blind 2-steps controlled superiority trial, with 2 parallel groups. Patients will be randomly assigned in a 2:1 ratio to receive Cobimetinib orally or placebo during the first 12-weeks step, allowing the determination of the primary criteria.